INTRODUCTION {#s1}
============

The Mouse Double Minute 2 homolog (MDM2) is a major regulator of the tumor suppressor p53. The levels of MDM2 and p53 are tightly regulated, as they act in a negative feedback loop where p53 induces *MDM2* transcription in response to genotoxic stress, whereas MDM2 binds, inhibits and directs p53 for proteasomal degradation by ubiquitinylation \[[@R1]--[@R4]\]. MDM2 hyperactivity through mechanisms such as gene amplification, increased transcription and enhanced translation is observed in many human cancers harboring wild-type *TP53* \[[@R5]--[@R7]\], and *MDM2* overexpression has been suggested to act as an alternative mechanism of p53 inactivation, thus promoting tumor growth.

While multiple single nucleotide polymorphisms (SNPs) have been identified in *MDM2* promoter regions, so far, only a few have been assessed with respect to potential biological functions. SNP309T\>G; rs2279744, located in the *MDM2* promoter P2, has been shown to increase *MDM2* expression by increasing the binding affinity between the promoter and the transcription factor Sp1 \[[@R8]\]. The same investigators found the SNP309G allele to be associated with early onset of several malignancies among individuals carrying *TP53* germline mutations (Li-Fraumeni syndrome) and also lower age at diagnosis of estrogen receptor (ER) rich breast cancer among individuals with wild-type *TP53* \[[@R9], [@R8]\]. Subsequent findings, with respect to the influence of SNP309 status on age at cancer onset as well as cancer risk have, however, been conflicting \[[@R10]--[@R17]\].

Recently, we reported a second *MDM2* promoter P2 polymorphism, SNP285G\>C; rs117039649 \[[@R18]\]. SNP285 is in complete linkage disequilibrium (LD) with SNP309; thus forming a distinct SNP285C/309G haplotype \[[@R18], [@R19]\]. The SNP285C allele diminish Sp1 binding to the *MDM2* promoter, and has been found to be associated with reduced risk for breast, ovarian and endometrial cancer \[[@R18], [@R20]--[@R22]\], but was not associated with prostate or lung cancer risk \[[@R20], [@R21], [@R23]\].

del1518 (rs3730485), is an insertion/deletion polymorphism of 40 bps in the *MDM2* promoter P1 \[[@R24], [@R25]\]. The del1518 del-allele has been shown to reduce transcription from the *MDM2* P1 promoter in some cell lines \[[@R26]\] and LD analysis has shown that the del1518 locus has a high LD with the SNP309 locus \[[@R24]\]. Some small studies have assessed the potential effects of the del1518-variant on cancer risk, and reported that the del1518 del allele may be associated with an increased risk for hepatocellular carcinoma \[[@R27]\] but to be unrelated to risk for several other cancer forms, including cancer of the lung \[[@R24]\], breast \[[@R25]\] ovary \[[@R28]\] or esophagus \[[@R29]\] in Chinese populations.

In the present case-control study we compared del1518 distribution across ethnic cohorts (Caucasians, African Americans and Han Chinese) and assessed the association of del1518 status with the risk for breast-, lung-, colon- and prostate cancer.

RESULTS {#s2}
=======

*MDM2* del1518 was determined in 7,081 Norwegian patients diagnosed with incidental cancers of the breast, colon, prostate or lung as well as 3,749 age-matched healthy individuals. In addition, to assess potential ethnic differences in del1518 distribution, we analyzed a cohort of 300 healthy African-Americans, and performed data mining from previously published del1518 genotyping of Chinese individuals (including 2,594 Chinese samples) \[[@R24], [@R25], [@R27]--[@R29]\].

Distribution of del1518 {#s2_1}
-----------------------

Among the 3,749 healthy Caucasian (Norwegian) individuals, we found the MAF of del1518 to be 0.42 and the genotype distribution to be in Hardy-Weinberg equilibrium (*p* = 0.5). Interestingly, this differed (*p* = 0.015) from the distribution observed in African Americans (MAF = 0.38). It also differed (*p* \< 1×10^−5^) from the distribution previously reported in Chinese populations (MAF = 0.30) \[[@R24], [@R25], [@R27]--[@R29]\] (comparison of genotype distribution between all three populations, p \< 1×10^−5^; Figure [1A](#F1){ref-type="fig"}).

![Genotype distribution and haplotype-tree\
**A.** Genotype distribution of *MDM2* SNP del1518 among Caucasians, African Americans and Chinese (Chinese data extracted from previous publications \[[@R24], [@R25], [@R27]--[@R29]\]). **B.** Haplotype-tree based on the three *MDM2* SNPs; del1518 (rs3730485), SNP309 (rs2279744) and SNP285 (rs117039649). The tree and the frequencies given for each haplotype are based on 3,749 healthy controls in the CONOR cohort and 300 healthy African Americans.](oncotarget-07-28637-g001){#F1}

Except for five individuals harboring the del1518 del/del -- SNP309TG genotype and two individuals harboring the del1518 ins/del -- SNP309GG (in the Caucasian cohort), the del1518 del variant was restricted to individuals carrying the SNP309TT or SNP309TG genotype, and del1518 del/del homozygosity was only seen among individuals carrying the SNP309TT genotype (Table [1](#T1){ref-type="table"}; Figure [1B](#F1){ref-type="fig"}). Thus, we observed a very strong linkage disequilibrium (LD) between the del1518 variant and SNP309 (D\'=0.999 for the healthy controls and D\' = 0.997 for the entire sample set, including cancer patients). This observation is in accordance with previous findings in a Chinese population \[[@R24]\].

###### Distribution of *MDM2* del1518 -- SNP309 haplotypes (alleles)

  Haplotype del1518 - 309   Healthy controls   Breast cancer   Colon cancer   Lung cancer   Prostate cancer                                 
  ------------------------- ------------------ --------------- -------------- ------------- ----------------- ------- ------ ------- ------ -------
  **ins -- T**              1561               20,82           675            19,66         646               21,08   572    21,49   1058   21,15
  **ins -- G**              2786               37,16           1296           37,74         1085              35,41   946    35,54   1854   3707
  **del -- T**              3150               42,01           1463           42,60         1331              43,44   1143   42,94   2087   41,72
  **del -- G**              1                  0,01            0              0             2                 0,007   1      0,04    3      0,06
  **Total**                 7498               100             3434           100           3064              100     2662   100     5002   100

*MDM2* del1518 and cancer risk {#s2_2}
------------------------------

In order to assess the potential impact of del1518-status on cancer risk, we first performed *in silico* analyses of putative de novo transcription factor binding sites created by the deletion. Applying the prediction algorithm in the JASPAR database \[[@R30]\] with default settings (cut off threshold of 80%), we found the breakpoint of the del-variant, with flanking nucleotides, to generate new binding sites for RORA (RAR-Related Orphan Receptor A), MEF2A (Myocyte Enhancer Factor 2A) and MIZF (MBD2 (methyl-CpG-binding protein)-interacting zinc finger protein) (Figure [2](#F2){ref-type="fig"}).

![*MDM2* promoter P1 del1518 break-point sequence context\
Novel transcription factor binding sites generated by the *MDM2* del1518 del allele, as predicted by the JASPAR database (indicated by horizontal lines under the sequence). The predicted binding scores are annotated in the brackets. \* indicates binding sites located on the reverse strand.](oncotarget-07-28637-g002){#F2}

To determine the potential correlation between *MDM2* del1518 status and cancer risk, we analyzed the distribution of this variant in large sample sets of incident cases of four major cancer forms (1,717 breast, 1,532 colon, 1,331 lung and 2,501 prostate cancer samples) drawn from the population-based Cohort of Norway (CONOR) \[[@R31]\] and compared the distribution to 3,749 matched controls without any cancer from the same cohort. The genotype distributions and the results from calculations of Odds Ratios (OR) between patients and controls are summarized in Table [2](#T2){ref-type="table"}.

###### *MDM2* del1518 distribution and cancer risk (OR)

  Cases/controls                                            Genotype del1518 n (%)   OR (95% CI) del1518   Fisher exact   OR (95% CI) del1518   Fisher exact                      
  --------------------------------------------------------- ------------------------ --------------------- -------------- --------------------- -------------- ------------------ -------
  **Healthy Controls**                                      1285 (34.3)              1777 (47.4)           687 (18.3)     1.00                  \-             1.00               \-
   Women                                                    636 (34.0)               877 (46.9)            359 (19.2)     1.00                  \-             1.00               \-
   Men                                                      649 (34.6)               900 (47.9)            328 (17.5)     1.00                  \-             1.00               \-
  **Colon cancer**                                          478 (31.2)               775 (50.6)            279 (18.2)     1.15 (1.01-1.31)      0.034          0.99 (0.85-1.16)   0.938
   Women                                                    237 (30.4)               393 (50.5)            149 (19.1)     1.18 (0.98-1.41)      0.077          1.00 (0.81-1.23)   1.000
   Men                                                      241 (32.0)               382 (50.7)            130 (17.3)     1.12 (0.94-1.35)      0.218          0.99 (0.79-1.23)   0.955
    Left side                                               190 (30.2)               331 (52.5)            109 (17.3)     1.21 (1.01-1.45)      0.045          0.93 (0.75-1.17)   0.577
    Right side                                              261 (31.5)               410 (49.5)            158 (19.1)     1.14 (0.97-1.33)      0.133          1.05 (0.87-1.27)   0.621
  **Lung cancer**                                           447 (33.6)               624 (46.9)            260 (19.5)     1.03 (0.90-1.18)      0.662          1.08 (0.92-1.27)   0.346
   Women                                                    155 (31.2)               247 (49.7)            95 (19.1)      1.14 (0.92-1.40)      0.261          1.00 (0.78-1.28)   1.000
   Men                                                      292 (35.0)               377 (45.2)            165 (19.8)     0.98 (0.83-1.16)      0.827          1.17 (0.95-1.43)   0.161
  **Breast cancer[^c^](#tfn_003){ref-type="table-fn"}**     581 (33.8)               809 (47.1)            327 (19.0)     1.01 (0.88-1.16)      0.944          0.99 (0.84-1.17)   0.932
  **Prostate cancer[^d^](#tfn_004){ref-type="table-fn"}**   836 (33.4)               1240 (49.6)           425 (17.0)     1.05 (0.93-1.19)      0.439          1.02 (0.85-1.22)   0.853

del/del + ins/del versus ins/ins

del/del versus ins/del + ins/ins

compared to female controls only

compared to male controls only

In overall assessments applying a dominant model, the del1518 del allele was associated with an increased risk of colon cancer (OR = 1.15; 95 % CI = 1.01 -- 1.31; Table [2](#T2){ref-type="table"}, Figure [3](#F3){ref-type="fig"}, [Supplementary Table S1](#SD1){ref-type="supplementary-material"}). Notably, this association was more pronounced among patients with left sided colon cancer (dominant model: OR = 1.21; 95 % CI = 1.01 - 1.45), compared to patients with right sided tumors (dominant model: OR = 1.14; 95 % CI = 0.97 -- 1.33; Table [2](#T2){ref-type="table"}, Figure [3](#F3){ref-type="fig"}, [Supplementary Table S1](#SD1){ref-type="supplementary-material"}). For the three other cancer forms, no statistically significant association between del1518 status and cancer risk was recorded (Table [2](#T2){ref-type="table"}, Figure [3](#F3){ref-type="fig"}, [Supplementary Table S1](#SD1){ref-type="supplementary-material"}).

![del1518 polymorphism and cancer risk\
Forest plot illustrating the effect of the *MDM2* del1518 polymorphism on the risk of breast-, colon-, lung- and prostate cancer, applying the dominant model (comparison of del1518 del/del + del/ins genotypes versus the ins/ins genotype).](oncotarget-07-28637-g003){#F3}

Potential interactions between *MDM2* del1518 status and *MDM2* SNP309 {#s2_3}
----------------------------------------------------------------------

In the samples investigated in this study we have previously reported the *MDM2* SNP309GG/TG genotypes to be associated with reduced risk of lung cancer among women, but not associated with risk of breast-, colon- or prostate cancer \[[@R20]\]. Given that the del1518 del was strongly linked to the SNP309T allele, we further refined our analyses by removing individuals harboring the SNP309GG genotype and assessed the effect of del1518 separately in individuals harboring the SNP309TG or SNP309TT genotype. Among individuals carrying the SNP309TT genotype, no association was recorded in either analysis (Table [3A](#T3A){ref-type="table"}, Figure [4A](#F4){ref-type="fig"}). However, among individuals with the SNP309TG genotype, the del1518 del allele was associated with increased risk for colon cancer (OR = 1.21; 95 % CI = 1.01 -- 1.46; Table [3B](#T3B){ref-type="table"}, Figure [4B](#F4){ref-type="fig"}), indicating a possible synergism between the del1518 del-allele and the SNP309G-allele.

###### *MDM2* del1518 among SNP309TT

  Cases/controls                                            Genotype del1518 n (%)   OR (95% CI) del1518   Fisher exact   OR (95% CI) del1518   Fisher exact                      
  --------------------------------------------------------- ------------------------ --------------------- -------------- --------------------- -------------- ------------------ -------
  **Healthy Controls**                                      155 (10.6)               623 (42.6)            686 (46.9)     1.00                  \-             1.00               
   Women                                                    70 (12.3)                311 (41.1)            359 (46.6)     1.00                  \-             1.00               
   Men                                                      85 (10.2)                312 (42.9)            327 (46.9)     1.00                  \-             1.00               
  **Colon cancer**                                          71 (11.3)                283 (44.9)            277 (43.9)     0.93 (0.69-1.26)      0.646          0.89 (0.74-1.07)   0.958
   Women                                                    34 (10.6)                140 (43.5)            148 (46.0)     0.89 (0.57-1.36)      0.576          0.90 (0.69-1.17)   0.463
   Men                                                      37 (12.0)                142 (46.3)            129 (4.8)      0.98 (0.65-1.48)      0.916          0.87 (0.67-1.14)   0.338
  **Lung cancer**                                           63 (11.1)                245 (43.2)            259 (45.7)     0.95 (0.70-1.29)      0.749          0.95 (0.79-1.16)   0.655
   Women                                                    23 (10.1)                110 (48.3)            95 (41.7)      0.93 (0.57-1.53)      0.797          0.76 (0.56-1.02)   0.081
   Men                                                      40 (11.8)                135 (39.8)            164 (48.4)     0.99 (0.67-1.48)      1.000          1.14 (0.88-1.47)   0.355
  **Breast cancer[^c^](#tfn_007){ref-type="table-fn"}**     66 (9.8)                 279 (41.5)            327 (48.7)     1.00 (0.67-1.37)      0.857          1.01 (0.82-1.24)   0.958
  **Prostate cancer[^d^](#tfn_008){ref-type="table-fn"}**   108 (10.9)               456 (46.2)            424 (42.9)     1.08 (0.80-1.47)      0.643          0.91 (0.75-1.11)   0.375

del/del + ins/del versus ins/ins

del/del versus ins/del + ins/ins

compared to female controls only

compared to male controls only

###### *MDM2* del1518 among SNP309TG

  Cases/controls                                            Genotype del1518 n (%)   OR (95% CI) del1518   Fisher exact                      
  --------------------------------------------------------- ------------------------ --------------------- -------------- ------------------ -------
  **Healthy Controls**                                      628 (35.2)               1154 (64.8)           \-             1.00               \-
   Women                                                    312 (35.5)               566 (64.5)                                              
   Men                                                      316 (35.0)               588 (65.0)                                              
  **Colon cancer**                                          221 (31.0)               492 (69.0)            \-             1.21 (1.01-1.46)   0.044
   Women                                                    109 (30.1)               253 (69.9)                           1.28 (0.98-1.67)   0.075
   Men                                                      112 (31.9)               239 (68.1)                           1.15 (0.88-1.49)   0.320
  **Lung cancer**                                           201 (34.7)               379 (65.3)            \-             1.03 (0.84-1.25)   0.841
   Women                                                    66 (32.5)                137 (67.5)                           1.14 (0.83-1.58)   0.462
   Men                                                      135 (35.8)               242 (64.2)                           0.96 (0.75-1.24)   0.797
  **Breast cancer[^b^](#tfn_010){ref-type="table-fn"}**     264 (33.3)               530 (66.8)            \-             1.11 (0.90-1.36)   0.328
  **Prostate cancer[^c^](#tfn_011){ref-type="table-fn"}**   386 (33.1)               782 (67.0)            \-             1.10 (0.94-1.29)   0.234

no observations since del1518 del is linked to SNP309T

compared to female controls only

compared to male controls only

![Impact of the del1518 polymorphism on cancer risk among SNP309\
Forest plots illustrating the effect of the *MDM2* del1518 polymorphism on the risk of breast-, colon-, lung- and prostate cancer, applying the dominant model (comparison of del1518 del/del + del/ins genotypes versus the ins/ins genotype) among individuals carrying the SNP309TT genotype **A.** and (del1518 del/ins versus ins/ins) among individuals harboring the SNP309TG genotype **B.** (Due to the strong linkage between the del1518 del-allele and the SNP309T-allele, the group of homozygous del/del was non-evaluable within individuals with the SNP309TG-genotype).](oncotarget-07-28637-g004){#F4}

Similar subgroup analyses of the three remaining cancer forms showed no association between del1518 status and risk for malignancy at any site (Table [3A](#T3A){ref-type="table"}--[3B](#T3B){ref-type="table"}, Figure [4A](#F4){ref-type="fig"}--[4B](#F4){ref-type="fig"}).

DISCUSSION {#s3}
==========

The findings by Levine\'s group \[[@R8]\] and our group \[[@R18]\], suggesting that both the *MDM2* promoter SNP\'s 309 and 285 may have an effect on cancer risk, implies the importance of fine tuning of MDM2 levels with respect to carcinogenesis, and also indicate that other *MDM2* promoter variants could potentially be of importance.

Assessments of the promoter P1 del1518 variant have previously been performed in a few relatively small Chinese cohorts \[[@R24], [@R25], [@R27]--[@R29]\]. In the present study, we determined the distribution of del1518 status in a large Caucasian cohort. A major strength of our study is the large number of cancer patients and controls compared to other studies assessing del1518-status with respect to cancer risk. Also, the population based design, using incident cancers (breast, lung, colon and prostate) for whom DNA samples were collected years prior to diagnosis and controls matched by gender, age, and residential area, is a strong feature.

In line with previous risk assessments in Chinese populations \[[@R24], [@R25], [@R28]\], we found no association between del1518 status and risk for cancer of the breast, lung or prostate. We did, however, observe a positive association with colon cancer risk. Somewhat surprisingly, we found an effect on colon cancer among individuals heterozygous, but not homozygous, for del1518. However, as the del1518 variant is linked to the SNP309T allele, homozygosity for del1518 is restricted to individuals harboring the SNP309TT genotype. Additionally, after stratifying our data according to SNP309 status, we found heterozygousity for the del1518 del allele to be associated with an increased risk of colon cancer among individuals carrying the SNP309TG genotype, but not among SNP309TT homozygous individuals. Although the statistical significance was borderline, this may indicate a synergistic effect of these two polymorphisms. Notably, studies on other genes have revealed that individuals harboring heterozygous mutations may be at risk of different diseases compared to homozygous carriers \[[@R32], [@R33]\]. Such effects may potentially differ between cancer forms as well; previously, we reported that the SNP285C allele significantly reduces the risk for breast cancer among SNP309GG homozygous individuals, whereas in ovarian cancer, the effect of SNP285C was significant among SNP309TG individuals only \[[@R20], [@R18]\]. Here, the possibility exists that del1518 may be detrimental in concert with SNP309G heterozygosity (individuals harboring the SNP309TG genotype), but not exert a similar effect among SNP309TT carriers.

Left sided and right sided colon cancers are known to be different with respect to histological and molecular characteristics \[[@R34]\], and also the genetic mechanisms initiating the tumorigenic process have been found to be dissimilar \[[@R35]\]. There are evidence that hereditary nonpolyposis colon cancer (HNPCC) in general are found in right sided colon cancer \[[@R36]\], while familial adenomatous polyposis (FAP) dominates in left sided colon cancer \[[@R37]\]. However, although we only observed an increased OR among individuals suffering from left sided colon cancer, a clear trend for increased risk was observed also among patients harboring right sided colon cancer. The lack of statistical significance in this group may be a result of limited statistical power. Thus, whether the del1518 polymorphism is associated with increased risk for both left sided -- and right sided colon cancer may need to be explored in independent populations.

Previously, we showed that *MDM2* SNP285 is part of a predicted estrogen response element (ERE), where both Sp1 and ERα may bind and affect tumorigenesis \[[@R21]\]. However, when assessing SNP285 and cancer risk among "gender neutral" cancer forms (i.e., lung and colon cancer), we observed only moderate gender differences \[[@R20]\]. In the present study, corresponding to our previous findings regarding SNP285, we found no gender specific effect of del1518 on cancer risk in either cancer form. Taken together, these data indicate that the effect on cancer risk of the germline variations in the *MDM2* promoter regions, in general, are more dependent on tissue type than on gender.

In conclusion, we find an association of del1518 with the risk of colorectal cancer and no association for cancer of the prostate, breast or lung. The finding for colon cancer, however, warrants confirmation by others.

MATERIALS AND METHODS {#s4}
=====================

Study populations {#s4_1}
-----------------

To assess potential impact of del1518 status on cancer risk, we genotyped this variant in blood DNA from 10,830 individuals drawn from the Norwegian population-based Cohort of Norway (CONOR) study \[[@R31]\], previously described in \[[@R20]\]. This sample set included 3,749 cancer-free controls as well as incident cases of four major cancer forms: cancer of the breast (n=1,717), prostate (n=2,501), lung (n=1,331) and colon (n=1,532).

The African-American cohort (n=300) was from the Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute Bethesda, USA. These samples were collected as part of an ongoing case control study with previously described inclusion criteria \[[@R38]\]. Briefly, population controls were identified from the Department of Motor Vehicles, MD, USA and frequency matched to cases by age and gender. Written informed consent was obtained from all participants, and the study was approved by the Institutional Review Boards of the participating institutions.

*In silico* predictions {#s4_2}
-----------------------

Potential novel binding sites for transcription factors, generated by the deletion variant of the *MDM2* del1518 polymorphism, were predicted using the JASPAR database \[[@R30]\] ([http://jaspardev.genereg.net](http://jaspardev.genereg.net/)). Predictions were made using the default settings of the database (cut off threshold of 80%).

*MDM2* del1518 genotyping {#s4_3}
-------------------------

All samples were genotyped for *MDM2* del1518 by using DNA extracted from peripheral white blood cells. The region of the *MDM2* promoter P1 containing the del1518 was amplified by PCR using the VWR Taq DNA Polymerase system (VWR), with a primer pair previously described \[[@R27]\]. The amplification was performed in a total reaction volume of 25 μl, containing 2.5 μl 10x Key Buffer, 0.2 mM dNTPs, 0.2 μM each primer, 1.25 U Taq polymerase and 1 μl template DNA (10-100 μg). The thermo-cycling conditions were an initial step of 94°C for 5 min, 35 cycles of 94°C for 30 sec, 58°C for 30 sec and 72°C for 30 sec, followed by a final elongation step of 72°C for 10 min. The PCR products were separated by electrophoresis in a 3% agarose gel and visualized by GelRed^TM^ Nucleic Acid Gel Stain (BIOTIUM). The del1518 insertion and deletion alleles were observed as 481 bps -- and 441 bps bands respectively.

All samples were previously genotyped for *MDM2* SNP285 and SNP309 status \[[@R20]\] using custom LightSNiP assays (TIB MOLBIOL Syntheselabor GmbH, Berlin, Germany) as described in detail elsewhere \[[@R39]\].

Statistical analysis {#s4_4}
--------------------

Potential deviations from Hardy-Weinberg equilibrium in cancer patients as well as healthy controls were evaluated using the Chi-square test. Possible associations between *MDM2* del1518 and cancer risk, both in total and in stratified groups, were estimated by Odds Ratios (OR) and Fisher exact tests. ORs are given with 95% confidence intervals (CI) and p-values from Fisher exact tests are given as two-sided and cumulative.

All statistical analyses were performed using the IBM SPSS statistics (version 19) software package.
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